FindTrial
Sign In

Retrospective Analysis of the Efficacy and Safety of TNF-a Inhibitors in the Treatment of Severe Drug Eruptions

Retrospective Analysis of the Efficacy and Safety of TNF-a Inhibitors in the Treatment of Severe Drug Eruptions

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098717
Enrollment
Unknown
Registered
2025-03-12
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe Drug Eruptions

Interventions

Trial group:None

Sponsors

Dermatology Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Cutaneous lesions presenting with cutaneous and mucosal manifestations accompanied by systemic involvement (diagnosed as severe drug eruption confirmed by histopathological examination when the causative drug allergen remains unidentified); 2. Lesions assessed and diagnosed as severe drug eruption by at least two independent dermatologists; 3. Completion of at least one full treatment course with standardized systemic pharmacotherapy, either as monotherapy or combination therapy; 4. Availability of complete follow-up documentation.

Exclusion criteria

Exclusion criteria: 1. Patients with missing critical study-related data/information; 2. Other circumstances deemed ineligible for inclusion based on investigator discretion.

Design outcomes

Primary

MeasureTime frame
Re-epithelialization Time;—

Secondary

MeasureTime frame
Time to Complete Healing of Skin and Mucosa ;Total Length of Hospital Stay (LOS);—

Countries

China

Contacts

Public ContactGuannan Zhu

Dermatology Hospital, Southern Medical University

zhuguannan@smu.edu.cn+86 20 8302 7560

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026